NasdaqCM:INOBiotechs
Is Inovio (INO) Turning Fresh DNA Medicine Data Into a More Coherent Investment Story?
Inovio Pharmaceuticals recently announced plans to release its Q1 2026 earnings after market close on May 13, 2026, alongside a conference call and upcoming scientific presentations on its DNA medicine pipeline for HPV-related diseases, cancer, and infectious diseases.
Investor attention has intensified as Inovio’s DNA vaccine and gene transfer programs gain visibility, supported by significant institutional ownership and new clinical data disclosures on candidates such as INO-3107 and its...